AbbVie has entered into a global research collaboration and option-to-license agreement with Neomorph to develop innovative molecular glue degraders for oncology and immunology. The deal, valued at up to US$1.64 B, leverages Neomorph's molecular glue discovery platform and aligns with AbbVie's strategic focus on expanding its oncology and immunology pipeline. This partnership provides Neomorph with the necessary funding to advance its research and development efforts, while AbbVie gains access to an advanced technology to address previously "undruggable" targets.